Evidence map›Paper›PMID 31396016›Full record

ArticleMediators of inflammation2019

Atorvastatin and Conditioned Media from Atorvastatin-Treated Human Hematopoietic Stem/Progenitor-Derived Cells Show Proangiogenic Activity

Witold N Nowak, Hevidar Taha, Joanna Markiewicz, Neli Kachamakova-Trojanowska, Jacek Stępniewski, Damian Klóska, Urszula Florczyk-Soluch, Rafał Niżankowski, Marzena Frołow, Zbigniew Walter and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Network Pharmacology Integrated with Transcriptomics Deciphered the Potential Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Witold N NowakDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.ORCID https://orcid.org/0000-0002-1526-3511
Hevidar TahaDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Joanna MarkiewiczDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.ORCID https://orcid.org/0000-0002-4168-9049
Neli Kachamakova-TrojanowskaDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Jacek StępniewskiDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Damian KlóskaDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Urszula Florczyk-SoluchDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Rafał Niżankowski2 Department of Internal Medicine, Jagiellonian University Medical College, Skawińska 8, 31-066 Kraków, Poland.
Marzena Frołow2 Department of Internal Medicine, Jagiellonian University Medical College, Skawińska 8, 31-066 Kraków, Poland.
Zbigniew WalterClinics of Hematology, University Hospital, Jagiellonian University Medical College, M. Kopernika 36, 31-501 Kraków, Poland.
Józef DulakDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.
Alicja JózkowiczDepartment of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 31-007 Kraków, Poland.ORCID https://orcid.org/0000-0002-7317-260X
Jagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid angiogenic cells (MAC) derive from hematopoietic stem/progenitor cells (HSPCs) that are mobilized from the bone marrow. They home to sites of neovascularization and contribute to angiogenesis by production of paracrine factors. The number and function of proangiogenic cells are impaired in patients with diabetes or cardiovascular diseases. Both conditions can be accompanied by decreased levels of heme oxygenase-1 (HMOX1), cytoprotective, heme-degrading enzyme. Our study is aimed at investigating whether precursors of myeloid angiogenic cells (PACs) treated with known pharmaceuticals would produce media with better proangiogenic activity

Indexed as

AC133 AntigenAntigens, CD34AspirinAtorvastatinCells, CulturedCulture Media, ConditionedHematopoietic Stem CellsHeme Oxygenase-1HumansImmunoassayIsothiocyanatesLeukocytes, MononuclearMetforminNeovascularization, PhysiologicPhenotypeResveratrolAC133 AntigenAntigens, CD34AspirinAtorvastatinCulture Media, ConditionedHeme Oxygenase-1IsothiocyanatesMetforminResveratrolsulforaphaneSulfoxides

Identifiers

PMID31396016
PMCPMC6664685
OpenAlexW2961807409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.